Literature DB >> 35058581

Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation.

Akihisa Kawajiri1, Takakazu Kawase2, Hidenori Tanaka3, Takahiro Fukuda4, Junichi Mukae5, Yukiyasu Ozawa6, Tetsuya Eto7, Naoyuki Uchida8, Takehiko Mori9,10, Takashi Ashida11, Tadakazu Kondo12, Makoto Onizuka13, Tatsuo Ichinohe14, Yoshiko Atsuta15,16, Satoko Morishima17, Junya Kanda12.   

Abstract

The role of matching human leukocyte antigen (HLA) haplotypes in unrelated allogeneic bone marrow transplantation (allo-BMT) remains unclear. Here, we imputed the HLA haplotypes of 3657 patients who received unrelated single HLA allele-mismatched allo-BMT, included from the Transplant Registry Unified Management Program (TRUMP) database, the Japanese registry program for hematopoietic transplantation, using mathematical methods. We successfully imputed the HLA haplotypes of both patients and donors in 1365 cases (37.3%) with ≥90% probability. Of the patients, 1326 (97.1%) and 39 (2.9%) were categorized into one-haplotype-matched and no-haplotype-matched groups, respectively. Disease-free survival was significantly worse in the no-haplotype-matched group. Multivariate analyses revealed that no-haplotype-match was an independent risk factor for reducing disease-free survival (hazard ratio, 1.54 [95% confidence interval: 1.01-2.36]; p = 0.047). However, the overall survival did not significantly differ between the groups. The incidence of grade III-IV acute and chronic graft-versus-host disease did not significantly differ between the groups. Furthermore, there were no significant differences in the cumulative incidences of relapse and non-relapse mortality between the groups. Our findings suggest that imputing haplotypes using a mathematical approach can help to avoid transplanting patients with donors who do not share matching haplotypes, thereby improving the outcome of allo-BMT.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35058581     DOI: 10.1038/s41409-021-01552-y

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.174


  22 in total

1.  Impact of highly conserved HLA haplotype on acute graft-versus-host disease.

Authors:  Satoko Morishima; Seishi Ogawa; Aiko Matsubara; Takakazu Kawase; Yasuhito Nannya; Koichi Kashiwase; Masahiro Satake; Hiroo Saji; Hidetoshi Inoko; Shunichi Kato; Yoshihisa Kodera; Takehiko Sasazuki; Yasuo Morishima
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

2.  A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians.

Authors:  Kornélia Szabó; Hilda Polyánka; Ágnes Kiricsi; Mónika Révész; Ida Vóna; Zsolt Szabó; Zsolt Bella; Edit Kadocsa; Lajos Kemény; Márta Széll; Andor Hirschberg
Journal:  Hum Immunol       Date:  2015-10-09       Impact factor: 2.850

3.  Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Takakazu Kawase; Hidenori Tanaka; Hiroto Kojima; Naoyuki Uchida; Kazuteru Ohashi; Takahiro Fukuda; Yukiyasu Ozawa; Kazuhiro Ikegame; Tetsuya Eto; Takehiko Mori; Toshihiro Miyamoto; Michihiro Hidaka; Souichi Shiratori; Minoko Takanashi; Yoshiko Atsuta; Tatsuo Ichinohe; Yoshinobu Kanda; Junya Kanda
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-07       Impact factor: 5.742

Review 4.  Autoimmune diseases and 8.1 ancestral haplotype: An update.

Authors:  C M Gambino; A Aiello; G Accardi; C Caruso; G Candore
Journal:  HLA       Date:  2018-06-19       Impact factor: 4.513

5.  Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients.

Authors:  Harriet Corvol; Julie Beucher; Pierre-Yves Boëlle; Pierre-François Busson; Céline Muselet-Charlier; Annick Clement; Felix Ratjen; Hartmut Grasemann; Judith Laki; Colin N A Palmer; J Stuart Elborn; Anil Mehta
Journal:  J Cyst Fibros       Date:  2011-10-10       Impact factor: 5.482

6.  Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and Marrow Transplantation.

Authors:  Yoshinobu Kanda; Junya Kanda; Yoshiko Atsuta; Yoshinobu Maeda; Tatsuo Ichinohe; Kazuteru Ohashi; Takahiro Fukuda; Koichi Miyamura; Hiroatsu Iida; Takehiko Mori; Koji Iwato; Tetsuya Eto; Keisei Kawa; Satoshi Morita; Yasuo Morishima
Journal:  Br J Haematol       Date:  2013-03-04       Impact factor: 6.998

Review 7.  The major histocompatibility complex: a model for understanding graft-versus-host disease.

Authors:  Effie W Petersdorf
Journal:  Blood       Date:  2013-07-22       Impact factor: 22.113

8.  Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study.

Authors:  N Ikeda; H Kojima; M Nishikawa; K Hayashi; T Futagami; T Tsujino; Y Kusunoki; N Fujii; S Suegami; Y Miyazaki; D Middleton; H Tanaka; H Saji
Journal:  Tissue Antigens       Date:  2015-02-27

9.  An original Eurasian haplotype, HLA-DRB1*14:54-DQB1*05:03, influences the susceptibility to idiopathic achalasia.

Authors:  Janette Furuzawa-Carballeda; Joaquín Zuñiga; Diana I Hernández-Zaragoza; Rodrigo Barquera; Eduardo Marques-García; Luis Jiménez-Alvarez; Alfredo Cruz-Lagunas; Gustavo Ramírez; Nora E Regino; Ramón Espinosa-Soto; Edmond J Yunis; Fernanda Romero-Hernández; Daniel Azamar-Llamas; Enrique Coss-Adame; Miguel A Valdovinos; Samuel Torres-Landa; Axel Palacios-Ramírez; Blanca Breña; Edgar Alejandro-Medrano; Axel Hernández-Ávila; Julio Granados; Gonzalo Torres-Villalobos
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

10.  Inheritance of the 8.1 ancestral haplotype in recurrent pregnancy loss.

Authors:  Astrid M Kolte; Henriette S Nielsen; Rudi Steffensen; Bernard Crespi; Ole B Christiansen
Journal:  Evol Med Public Health       Date:  2015-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.